Estudo randomizado de fase 1/2 | Segurança e imunogenicidade de vacina inativada contra COVID-19 (BBIBP-CorV) em crianças e adolescentes de 3 a 17 anos de idade.

Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial – The Lancet Infectious Diseases

Conteúdo relacionado: Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.